|
|
Article: Sangamo BioSciences Completes Enrollment and Treatment in Phase 1 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy.
- Article from:
- PR Newswire
- Article date:
- November 30, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
On Track to Initiate Phase 2 Clinical Trial in 2006
RICHMOND, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. today announced that it has completed subject enrollment and treatment in its Phase 1 study of SB-509 in subjects with mild to moderate diabetic neuropathy. SB-509 is a novel ZFP Therapeutic(TM) designed to upregulate the expression of the patient's own vascular endothelial growth factor (VEGF) gene to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy. Sangamo expects to announce results from this study in the first half of 2006 and to initiate a Phase 2 clinical ...